Jafron BiomedicalLtd Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Fan Dong

Chief executive officer

CN¥3.7m

Total compensation

CEO salary percentage	n/a
CEO tenure	14yrs
CEO ownership	46.4%
Management average tenure	1.7yrs
Board average tenure	3.3yrs

Recent management updates

Recent updates

CEO

Fan Dong (54 yo)

14yrs

Tenure

CN¥3,741,000

Compensation

Mr. Fan Dong serves as Chairman of Board of Directors and General Manager at Jafron Biomedical Co., Ltd. He serves as Director since April 27, 2023 at Jafron Biomedical Co.,Ltd. He served as Company Secret...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Fan Dong	Chairman of Board of Directors & GM	no data	CN¥3.74m	46.39% CN¥ 9.5b
Xueyun Liao	Director & Financial Director	1.4yrs	CN¥500.50k	0.019% CN¥ 3.9m
De Zhi Li	Deputy General Manager	no data	CN¥865.40k	0.46% CN¥ 94.9m
Xian Min Tang	Deputy GM & Director	no data	CN¥2.65m	2.79% CN¥ 572.5m
Aijun Wu	Deputy General Manager	4.3yrs	CN¥2.44m	0.032% CN¥ 6.5m
Rui Wang	General Manager	less than a year	CN¥510.40k	no data
Cong Huang	Board Secretary	2yrs	CN¥455.20k	0.00045% CN¥ 92.3k

1.7yrs

Average Tenure

54yo

Average Age

Experienced Management: 300529's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Fan Dong	Chairman of Board of Directors & GM	14yrs	CN¥3.74m	46.39% CN¥ 9.5b
Xueyun Liao	Director & Financial Director	less than a year	CN¥500.50k	0.019% CN¥ 3.9m
Xian Min Tang	Deputy GM & Director	14yrs	CN¥2.65m	2.79% CN¥ 572.5m
Claudio Ronco	Member of Global Advisory Board	3.3yrs	no data	no data
Feng Li	Non-Independent Director	4.4yrs	CN¥1.08m	0.10% CN¥ 20.5m
Xiaohong Peng	Chairman of Supervisory Board	4.4yrs	no data	no data
Wen Lei	Non-Independent Director	4.4yrs	CN¥177.20k	no data
Rinaldo Bellomo	Member of Global Advisory Board	3.3yrs	no data	no data
Thomas Rimmelé	Member of Global Advisory Board	3.3yrs	no data	no data
John Prowle	Member of Global Advisory Board	3.3yrs	no data	no data
Antoine Schneider	Member of Global Advisory Board	3.3yrs	no data	no data
Olivier Joannes-Boyau	Member of Global Advisory Board	3.3yrs	no data	no data

3.3yrs

Average Tenure

54yo

Average Age

Experienced Board: 300529's board of directors are considered experienced (3.3 years average tenure).

Jafron BiomedicalLtd Management

Management criteria checks 2/4

Key information

Recent management updates

Jafron Biomedical Co.,Ltd., Annual General Meeting, May 20, 2024

High number of new directors

High number of new and inexperienced directors

High number of new and inexperienced directors

Recent updates

Second quarter 2024 earnings released: EPS: CN¥0.34 (vs CN¥0.10 in 2Q 2023)

Jafron Biomedical Co.,Ltd. to Report First Half, 2024 Results on Aug 08, 2024

Dividend reduced to CN¥0.40

Now 20% overvalued after recent price rise

Investor sentiment improves as stock rises 18%

Jafron Biomedical Co.,Ltd., Annual General Meeting, May 20, 2024

Jafron Biomedical Co.,Ltd. Proposes Final Dividend for the Year 2023

First quarter 2024 earnings released: EPS: CN¥0.35 (vs CN¥0.25 in 1Q 2023)

Jafron Biomedical Co.,Ltd. to Report Q1, 2024 Results on Apr 26, 2024

Investor sentiment improves as stock rises 15%

Investor sentiment improves as stock rises 16%

Jafron Biomedical Co.,Ltd. to Report Fiscal Year 2023 Results on Apr 26, 2024

New minor risk - Earnings quality

Third quarter 2023 earnings released: EPS: CN¥0.18 (vs CN¥0.16 in 3Q 2022)

Investor sentiment improves as stock rises 16%

Jafron Biomedical Co.,Ltd. to Report Q3, 2023 Results on Oct 30, 2023

New minor risk - Profit margin trend

Second quarter 2023 earnings released: EPS: CN¥0.10 (vs CN¥0.51 in 2Q 2022)

Jafron Biomedical Co.,Ltd. to Report First Half, 2023 Results on Aug 23, 2023

Jafron Biomedical Co.,Ltd. Announces Cash Dividend on A Shares for the Year 2022, Payable on 31 May 2023

High number of new directors

Full year 2022 earnings released: EPS: CN¥1.12 (vs CN¥1.49 in FY 2021)

High number of new and inexperienced directors

Investor sentiment deteriorated over the past week

Third quarter 2022 earnings released: EPS: CN¥0.16 (vs CN¥0.30 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.51 (vs CN¥0.43 in 2Q 2021)

Jafron Biomedical Co.,Ltd. Implements Final Cash Dividend (A Shares) for 2021, Payable on 10 June 2022

Jafron Biomedical Co.,Ltd. Approves Profit Distribution

High number of new and inexperienced directors

Jafron Biomedical Co.,Ltd. Announces the Profit Distribution Proposal for 2021

Full year 2021 earnings released: EPS: CN¥1.49 (vs CN¥1.10 in FY 2020)

Investor sentiment deteriorated over the past week

Third quarter 2021 earnings released: EPS CN¥0.30 (vs CN¥0.24 in 3Q 2020)

Jafron Biomedical Co.,Ltd. (SZSE:300529) commences an Equity Buyback Plan for CNY 500 million worth of its shares, under the authorization approved on September 14, 2021.

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS CN¥0.43 (vs CN¥0.32 in 2Q 2020)

Investor sentiment deteriorated over the past week

Jafron Biomedical Co.,Ltd. Announces 2020 Final Profit Distribution, Payable on 12 May 2021

Full year 2020 earnings released: EPS CN¥1.10 (vs CN¥0.73 in FY 2019)

Jafron Biomedical Co.,Ltd. to Report Fiscal Year 2020 Results on Apr 01, 2021

New 90-day high: CN¥90.54

New 90-day high: CN¥84.63

New 90-day low: CN¥63.65

Market pulls back on stock over the past week

Market pulls back on stock over the past week

New 90-day high: CN¥78.75

Third quarter earnings released

Jafron Biomedical Co.,Ltd. to Report Q3, 2020 Results on Oct 21, 2020

New 90-day low: CN¥64.37

New 90-day high - CN¥77.44

Earnings released

Jafron Biomedical Co.,Ltd. to Report First Half, 2020 Results on Aug 26, 2020

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age